Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  30.00 0.73% 4,145.00 4,090.00 4,200.00 4,145.00 4,115.00 4,115.00 3,697 08:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 29.7 216

Bioventix Share Discussion Threads

Showing 1301 to 1322 of 1325 messages
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
31/3/2021
17:35
I think Bioventix own 10% Intuitive Investments Group plc Investment in CardiNor AS Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per cent. interest in CardiNor's enlarged share capital. CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: hxxps://cardinor.com/ . In the year ended 31 December 2020 , per CardiNor's unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.
valustar1
30/3/2021
09:35
Anything revealing at Mello on Biovenrix? Thanks N
nigeldoug1
29/3/2021
21:39
StrollingMolby, Thank you for the explanation
piedro
29/3/2021
18:50
Piedro, yes I initially thought there must be a mistake or exceptional adjustments made, but then recalled the last half-year results to Dec'19 were restated due to a sales rebate not being entered into the accounting system, a pretty silly mistake really and not clear how that could have happened. This is from the correction note on 31 March 2020: Correction - Unaudited Interim Results for the six months ended 31 December 2019 The Company has become aware that due to an administration error a sales rebate of $219k (£167k) was not entered into the accounting system. Consequently revenues for the six month period were £5.1m not the £5.3m as reported on 30 March 2020. Pre tax profits were £4.1m as opposed to £4.3m as previously stated. The cash figure and interim dividend remain unchanged. HTTPS://www.investegate.co.uk/bioventix-plc--bvxp-/prn/correction---interim-results/20200331174737P8321/
strollingmolby
29/3/2021
17:14
Please can someone explain me the following ... In these Interim Results TURNOVER for the 6 months ended 31/12/2019 = £5,098,588 whereas from the previous Interim Results TURNOVER for the 6 months ended 31/12/2019 = £5,265,270 ..... TIA.
piedro
29/3/2021
16:22
Wildshot - what is the point of incurring hedging cost and time on fx? Why not just take the gains and losses as they arise instead of delaying them - which is all that hedging effectively does, at a cost.
trident5
29/3/2021
15:21
Hi Boros10, thanks for doing the session. If possible could you cover the forex management and whether they are likely to hedge in future to reduce the impact on margins by exchange gains/losses?
wildshot
29/3/2021
15:10
Leon - I second nigeldough1 - would like to understand more about the pollution project - sounds a bit different from the usual type of blood test.
sharw
29/3/2021
14:45
Investor's Champion comment: As always, Bioventix swiftly converted profits into cash, with the operating cash inflow £3.3m and free cash inflow £3.2m, leaving period end cash of £5.8m well able to support a 20% increase in the first interim dividend to 43p per share.
energeticbacker
29/3/2021
09:58
Nice to see the word Cannabis in there!
igbertsponk
29/3/2021
09:33
LeonMany thanks for your post.What I would like to understand from Peter is how he plans to monetise the polution opportunity.ThanksNigel B
nigeldoug1
29/3/2021
08:26
"High-sensitivity troponin revenues from both Siemens Healthineers and licensees are estimated to have been c.£280k in the period, implying a more than doubling of revenues in H1 FY 2020, which implies sequential six-month growth of c.40%. Troponin now accounts for c.6% of revenues." From the finnCap research note which is available for free upon registration.
gsbmba99
29/3/2021
08:21
Topped up on open. Suet
suetballs
29/3/2021
08:14
Boros10 - my question would be - is there a succession plan in place? Thanks.
trident5
29/3/2021
08:09
Good morning Boros10, I look forward to watching the interview this evening. As mentioned in my post earlier today, "Sales relating to troponin antibodies grew significantly once again during the period" - would be useful to get more detail on "grew significantly" in terms of numbers if possible.
spann_703
29/3/2021
08:01
With significant Covid 19 disruption from October through to the end of December and GBP advancing strongly against the USD and EUR I was braced for worse. Revenues for H1 21 were actually up 2% versus H2 2020 (sequential) which is encouraging. The business was hot badly following the initial global lockdowns in March 2020 with royalty revenues in H2 2020 dropping by as much as 26% over the previous six months. This dramatic decline was masked by a 48% sequential increase in purified SMA sales. It would have been helpful had management disclosed the royalty and purified SMA sale split for the period just ended but I imagine royalty revenues have partially recovered. I'll be quizzing Peter Harrison on this point and others on tonight's Mello Monday interview. If you have any questions you'd like me to ask Peter please let me know below.
boros10
29/3/2021
07:52
In fairness the only real negative was the exchange rate loss which was already known. Given turnover is up at a time when patients presenting is on relative hold is fantastic news. Looks as though troponin is proving to be a winner.All set fair for when we get through Covid.
nigeldoug1
29/3/2021
07:44
Will be interesting to see how the market reacts today, with a very un-Bioventix-like drop of ~9% in profit. "Sales relating to troponin antibodies grew significantly once again during the period." - a shame there isn't any greater visibility in terms of figures on this growth, especially as this is expected to be one of the more important areas for the company over the next 5 years. "ongoing evidence that patients are choosing not to present to healthcare professionals" - have to wonder how long this state of affairs is likely to continue, although doubtful anyone really knows. Good to see that the cash-generative nature of the business means they can hike the dividend by 20% in these comparatively lean times.
spann_703
29/3/2021
07:24
Numbers better than I expected and dividend up 20%. Suet
suetballs
26/3/2021
17:28
Fingers crossed for Monday's announcement. Might not be great but I'm in for the long haul as the model is so appealing.
nigeldoug1
24/3/2021
15:47
I decided that I remembered a pattern to BVXP at results time (Monday). It would go up beforehand and slump on the announcement - because it was the usual pattern. So, I would sell on Friday and buy back when it fell on Monday. I checked back over a couple of years and it isn’t the usual pattern - so I wont! Now what’ll happen is that it’ll fall back on the Monday announcement! apad
apad
24/3/2021
15:25
Worth holding just for the dividend
lancasterbomber
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
ADVFN Advertorial
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210411 14:03:01